The Company is targeting approximately $20 million of Annualised Run-Rate EBITDASO on annualised run-rate revenues of approximately $75 million by Q2, 2025. This outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
- Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- Trinity Biotech regains compliance with Nasdaq minimum closing bid price rule
- Trinity Biotech trading halted, news pending
- Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
